Active Ingredient History
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Allergy and Immunology (Phase 2)
Antigens, CD (Phase 1)
Antiphospholipid Syndrome (Phase 2/Phase 3)
Arthritis, Rheumatoid (Phase 2)
Cryoglobulinemia (Phase 2)
Emphysema (Phase 2)
Glomerulonephritis, Membranous (Phase 2)
Graft vs Host Disease (Phase 1)
Granulomatosis with Polyangiitis (Phase 2)
Healthy Volunteers (Phase 1)
Immunoglobulin G4-Related Disease (Phase 4)
Kidney Transplantation (Phase 2)
Leukemia, Lymphoid (Phase 2)
Lupus Nephritis (Phase 3)
Multiple Sclerosis (Phase 2)
Myasthenia Gravis (Phase 2)
Myositis (Phase 2/Phase 3)
Nephrotic Syndrome (Phase 2)
Neuromyelitis Optica (Phase 1/Phase 2)
Organ Transplantation (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Purpura (Phase 2)
Scleroderma, Systemic (Phase 2)
Sjogren's Syndrome (Phase 2)
Vasculitis (Phase 3)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
